Senate Finance committee chair Ron Wyden (D-OR)(Graeme Sloan/Sipa USA)(Sipa via AP Images)

July 27, 2022 02:07 PM EDT

Senate Finance chair calls on Merck and Abbott to comply with his investigation into their offshore tax schemes

Zachary Brennan

Senior Editor

Senate Finance committee chair Ron Wyden (D-OR) on Wednesday sent follow-up letters to Merck and Abbott after both companies failed to answer questions and comply …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Senate Finance chair calls on Merck and Abbott to comply with his investigation into their offshore tax schemes

Zachary Brennan

Senior Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Exclusive: Florida cancer biotech raises $100M Series A

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Sen­ate Fi­nance chair calls on Mer­ck and Ab­bott to com­ply with his in­ves­ti­ga­tion in­to their off­shore tax schemes

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Senate Finance chair calls on Merck and Abbott to comply with his investigation into their offshore tax schemes

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Exclusive: Florida cancer biotech raises $100M Series A

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients